Is FMC Corporation (NYSE: FMC) for sale? What the 2026 strategic review means for its future

FMC Corporation (NYSE: FMC) announced a sweeping 2026 strategic review that could result in a full sale of the company, alongside a fourth quarter earnings report that reflected continued pricing pressure, asset divestitures, and a $1.72 billion goodwill impairment. The Board of Directors has authorized the exploration of multiple options to unlock shareholder value, including the potential sale of the company, amid aggressive balance sheet reconfiguration and a shifting post-patent portfolio.

The move marks a critical juncture for FMC Corporation, which is contending with declining revenues and profitability driven by commodity pressures on legacy products such as Rynaxypyr, weaker volumes in Latin America and Asia, and a slower-than-expected ramp-up in next-generation active ingredients. While the company emphasizes its commitment to operational execution in 2026, the decision to pursue strategic alternatives signals that internal improvements may no longer be enough to sustain long-term value creation under current ownership.

Why is FMC Corporation exploring a potential full sale or other strategic alternatives in 2026?

At the core of FMC Corporation’s review is a rapidly evolving agri-chemical environment in which legacy patent expirations, regulatory pressures, and partner renegotiations are squeezing margins. The centerpiece asset Rynaxypyr, which once delivered outsized margins, has entered its post-patent era, leaving the company exposed to price compression in several geographies. This challenge has been compounded by a decline in cost-plus revenue from diamide partners and broader competitive erosion.

Faced with these structural pressures, FMC Corporation is implementing a multi-pronged response. It plans to reduce $1 billion in debt through asset sales, including the previously disclosed divestiture of its India commercial business. The company is simultaneously trying to reposition its portfolio by advancing commercialization of four newer active ingredients — Isoflex, fluindapyr, Dodhylex, and rimisoxafen — which are now expected to generate between $300 million and $400 million in 2026 revenue, up more than 75 percent year-on-year.

However, this growth comes off a modest base. In 2025, these new actives brought in only $200 million — well below the company’s original $250 million target — primarily due to regulatory delays such as the late registration of Isoflex in Great Britain. The company still believes these actives represent transformative potential, but it now concedes that additional investment and scale may be required to fully unlock that upside, which is why the Board is actively weighing outside participation or ownership.

How does the 2025 performance inform FMC Corporation’s strategic inflection point?

The company’s financials underscore the urgency behind the strategic review. For the full year 2025, FMC Corporation posted revenue of $3.47 billion, down 18 percent on a GAAP basis and 8 percent excluding India. Adjusted EBITDA dropped 7 percent to $843 million, while adjusted earnings per share fell 15 percent to $2.96. GAAP net loss for the year totaled $2.24 billion, driven largely by a non-cash goodwill impairment of $1.72 billion in the fourth quarter, which was triggered by continued stock price deterioration.

The fourth quarter alone saw a 12 percent drop in revenue, with a sharp 33 percent decline in adjusted EPS and 17 percent fall in EBITDA, highlighting a deterioration in pricing power for Rynaxypyr and persistent volume headwinds. Notably, revenue in Asia excluding India declined significantly, and even Latin America, typically a stronghold for FMC Corporation, failed to deliver meaningful offset due to elevated competition.

Regionally, North America delivered modest resilience with $1.1 billion in full-year sales, while Europe, the Middle East, and Africa saw flat-to-slightly-increased performance. The outlier remains India, which posted negative revenue figures in the fourth quarter as the sale process advanced, complicating comparisons but reinforcing the company’s divestment-driven strategy.

What does the 2026 guidance reveal about management’s expectations going forward?

FMC Corporation’s 2026 guidance reflects continued caution. At the midpoint, full-year revenue is projected to decline 5 percent to approximately $3.70 billion, with adjusted EBITDA expected to fall another 17 percent to roughly $700 million. Adjusted EPS is forecast to plunge by 41 percent to between $1.63 and $1.89. These estimates assume India is fully excluded from the business and that price erosion — especially on Rynaxypyr — persists into 2026.

Despite this weak topline guidance, the company expects improved volumes in its branded portfolio and active ingredient launches, which could moderate some of the pricing impact. FMC Corporation also expects cost efficiencies to materialize more substantially in later quarters, as Q1 is expected to be especially challenging with tariffs and manufacturing costs creating a temporary drag. First quarter EBITDA margins are forecast to be unusually low before normalizing through the year.

The outlook also includes negative free cash flow of up to $65 million, signaling tight financial flexibility even as the company undertakes asset sales and licensing agreements to shore up its balance sheet. From an investor lens, the combination of high debt, earnings pressure, and operational restructuring makes the company vulnerable — and simultaneously a potential acquisition target if strategic buyers see long-term value in its differentiated pipeline and global reach.

Which companies could emerge as strategic buyers or partners for FMC Corporation?

Given the crop protection industry’s ongoing consolidation, a number of suitors could theoretically emerge if FMC Corporation decides to pursue a full or partial sale. Potential candidates include BASF, Corteva, Syngenta Group (backed by China National Chemical Corporation), or even private equity consortiums looking to scale biotech-driven agribusiness platforms. FMC Corporation’s combination of post-patent cash flows, newer actives in growth markets, and a global regulatory footprint could appeal to acquirers seeking pipeline diversity and operational leverage.

However, any transaction will require navigating multiple layers of complexity, including ongoing liabilities in India, geopolitical risks tied to tariffs and export controls, and the restructuring burden embedded in the core portfolio. Investors will also weigh the price and timing of a potential sale against FMC Corporation’s ability to self-correct and ride out its post-patent transition. There is also the risk that a failed review process, or one without a premium takeout offer, could further erode market confidence in the standalone business.

What’s the broader industry signal behind FMC Corporation’s strategic review?

Beyond the company itself, FMC Corporation’s decision to explore strategic alternatives is a signal that the agricultural inputs sector is entering a new maturity phase. Patent cliffs, regulatory scrutiny on chemical usage, biologicals competition, and climate-driven volatility are reshaping margin structures across the industry. Companies that once thrived on a blockbuster chemistry model now face demands for portfolio renewal, digital integration, and sustainability-driven R&D cycles.

For institutional investors, the case of FMC Corporation also represents a test of capital discipline. Despite a credible scientific track record and diversified reach, its stock has faced steady pressure due to declining returns, limited cash conversion, and slower-than-expected monetization of new pipeline assets. The $1.72 billion impairment, in particular, is not just an accounting charge — it is a reflection of revised long-term value perception.

As the strategic review unfolds, competitors may also accelerate their own internal audits. Whether FMC Corporation ends up being acquired, broken up, or reinvested in with external capital, the larger message is clear: scale and science alone are no longer sufficient without sharper portfolio strategy and capital efficiency.

Key takeaways: What does FMC Corporation’s 2026 strategic review mean for the sector?

• FMC Corporation’s Board has approved the exploration of strategic options, including a potential full sale of the company.
• The company reported a $2.24 billion net loss in 2025, driven by a non-cash goodwill impairment and weakening portfolio margins.
• 2026 revenue is forecast to decline 5 percent, with adjusted EPS expected to fall by 41 percent year-on-year.
• Rynaxypyr’s post-patent price erosion continues to weigh heavily on top-line and EBITDA performance.
• Four new active ingredients are projected to generate $300 million to $400 million in 2026, a 75 percent increase from 2025.
• FMC Corporation plans to reduce $1 billion in debt via asset sales, including the India business, to improve balance sheet health.
• First quarter of 2026 is expected to be particularly weak, with low EBITDA margins and negative earnings per share.
• The strategic review comes amid increased industry pressure from generics, climate volatility, and input regulation.
• Potential acquirers could include large crop protection companies or private equity groups focused on ag-tech scale-ups.
• Investor sentiment remains cautious, with the outcome of the review likely to reshape FMC Corporation’s trajectory and influence broader sector expectations.